These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36959376)

  • 1. The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study.
    Hall LA; McKay SC; Halle-Smith J; Soane J; Osei-Bordom DC; Goodburn L; Magill L; Pinkney T; Radhakrishna G; Valle JW; Corrie P; Roberts KJ;
    Br J Cancer; 2023 May; 128(10):1922-1932. PubMed ID: 36959376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States.
    Paluri R; Laursen A; Gaeta J; Wang S; Surinach A; Cockrum P
    Oncologist; 2022 Jun; 27(6):e518-e523. PubMed ID: 35285490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of pancreatic cancer treatment and survival disparities in Florida throughout the Covid-19 pandemic.
    Telisnor G; Lim A; Zhang Z; Lou X; Nassour I; Salloum RG; Rogers SC
    J Natl Med Assoc; 2024 Aug; 116(4):328-337. PubMed ID: 39107147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of the COVID-19 pandemic on patients with pancreatic cancer.
    Salirrosas O; Vega EA; Panettieri E; Salehi O; Kozyreva O; Harandi H; Ganta S; Conrad C
    J Gastrointest Surg; 2024 Jun; 28(6):830-835. PubMed ID: 38570231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age and prognosis in patients with pancreatic cancer: a population-based study.
    van Dongen JC; van der Geest LGM; de Meijer VE; van Santvoort HC; de Vos-Geelen J; Besselink MG; Groot Koerkamp B; Wilmink JW; van Eijck CHJ;
    Acta Oncol; 2022 Mar; 61(3):286-293. PubMed ID: 34935577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival.
    Heller DR; Nicolson NG; Ahuja N; Khan S; Kunstman JW
    JAMA Surg; 2020 Feb; 155(2):e195047. PubMed ID: 31800002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of the California state lockdown during the COVID-19 pandemic on management of patients with pancreatic ductal adenocarcinoma.
    Oviedo P; Burns S; Chen WP; Mandl HK; Rosso C; Radgoudarzi N; Crosetti A; Zamora S; Perry LM; Bold RJ; Labora AN; Donahue TR; Maker A; Valerin JB; Zell JA; White RR
    J Surg Oncol; 2024 Aug; 130(2):276-283. PubMed ID: 38894577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy.
    Sugawara T; Rodriguez Franco S; Sherman S; Kirsch MJ; Colborn K; Ishida J; Grandi S; Al-Musawi MH; Gleisner A; Schulick RD; Del Chiaro M
    JAMA Oncol; 2023 Mar; 9(3):316-323. PubMed ID: 36480190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
    Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
    J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the COVID-19 Pandemic on Outcomes for Patients with Lung Cancer Receiving Curative-intent Radiotherapy in the UK.
    Fornacon-Wood I; Banfill K; Ahmad S; Britten A; Carson C; Dorey N; Hatton M; Hiley C; Thippu Jayaprakash K; Jegannathen A; Kidd AC; Koh P; Panakis N; Peedell C; Peters A; Pope A; Powell C; Stilwell C; Thomas B; Toy E; Wicks K; Wood V; Yahya S; Price G; Faivre-Finn C
    Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):e593-e600. PubMed ID: 37507280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
    Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal timing and treatment strategy for pancreatic cancer.
    Gamboa AC; Rupji M; Switchenko JM; Lee RM; Turgeon MK; Meyer BI; Russell MC; Cardona K; Kooby DA; Maithel SK; Shah MM
    J Surg Oncol; 2020 Sep; 122(3):457-468. PubMed ID: 32470166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study.
    Liang L; Ding Y; Yu Y; Liu K; Rao S; Ge Y; Zeng M
    BMC Med Imaging; 2021 Apr; 21(1):75. PubMed ID: 33902469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disparities in Receipt of Adjuvant Therapy After Upfront Surgical Resection for Pancreatic Ductal Adenocarcinoma.
    Anteby R; Blaszkowsky LS; Hong TS; Qadan M
    Ann Surg Oncol; 2023 Apr; 30(4):2473-2481. PubMed ID: 36585536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of an Inter-Professional Clinic on Pancreatic Cancer Outcomes: A Retrospective Cohort Study.
    Moffat GT; Coyne Z; Albaba H; Aung KL; Dodd A; Espin-Garcia O; Moura S; Gallinger S; Kim J; Fraser A; Hutchinson S; Moulton CA; Wei A; McGilvray I; Dhani N; Jang R; Elimova E; Moore M; Prince R; Knox J
    Curr Oncol; 2024 May; 31(5):2589-2597. PubMed ID: 38785475
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of Immunotherapy after Resection of Pancreatic Cancer.
    Tran TB; Maker VK; Maker AV
    J Am Coll Surg; 2019 Jul; 229(1):19-27.e1. PubMed ID: 30742911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma.
    Mehtsun WT; McCleary NJ; Maduekwe UN; Wolpin BM; Schrag D; Wang J
    JAMA Oncol; 2022 Jan; 8(1):88-95. PubMed ID: 34854874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of care fragmentation on the outcomes of patients receiving neoadjuvant and adjuvant therapy for pancreatic adenocarcinoma.
    Brown ZJ; Labiner HE; Shen C; Ejaz A; Pawlik TM; Cloyd JM
    J Surg Oncol; 2022 Feb; 125(2):185-193. PubMed ID: 34599756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.